Cyprus Pharma Report
24/10/2018
Through interviews with the heads of some of India’s leading domestic pharmaceutical companies, this report delves into the biologics, biosimilars and new chemical entities being developed in India and taken abroad; the nation’s hubs of development and innovation,…
A light regulatory touch has long attracted companies to establish R&D and manufacturing plants for generic pharmaceuticals in Malta in the knowledge that products developed on the island can be launched globally immediately on the expiry of the originator drug – a…
With a fresh, business-minded administration in place, economic growth, a burgeoning middle class, and a greater openness towards cooperation between the public and private sectors, the fundamentals are there for Ecuador’s life sciences industry to shine. Medicine sales…
With GDP growth at 4.6% for 2017, pharma market growth of 4.2%, 38 million people, and a strategic location in the center of Europe, Poland has solid foundations for success in healthcare and the life sciences. The situation is improving for both generics companies and…
The Baltics Pharma Report 2018
18/04/2018
While Lithuania, Latvia and Estonia have a lot in common – small, high-income economies and Eurozone members situated on the Eastern coast of the Baltic Sea – it would be inadvisable to consider the Baltic states as one homogenous block. This report explores the…
India can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.…